nach oben

Erschienen in:

01.01.2009 | Review

Clinical observations programme in SpA: disease parameters, treatment options and practical management issues

verfasst von: Dirk Elewaut, Filip Van den Bosch, Gust Verbruggen, Filip de Keyser, Bert Vander Cruyssen, Herman Mielants

Erschienen in: Rheumatology International | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Spondyloarthritides (SpAs) are a cluster of chronic inflammatory rheumatic diseases that typically involve inflammation of axial and peripheral joint or tendon and ligament insertions, distinct radiographic changes and diverse extra-articular features. Conventional treatments relieve the signs and symptoms but do not prevent disease progression. TNFα inhibitors provide clinicians with the potential to treat the underlying pathology and to alter disease progression. By targeting the underlying inflammatory mechanisms, TNFα blockade can treat any extra-articular manifestations of SpA.

Moll JM, Haslock I, Macrae IF, Wright V (1974) Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s syndrome, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 53:343–364. doi:10.1097/00005792-197409000-00002 CrossRef

Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, The European Spondylarthropathy Study Group et al (1991) The European Spondyloarthroapthy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227. doi:10.1002/art.1780341003 PubMedCrossRef

Boyer GS, Templin DW, Bowler A, Lawrence RC, Heyse SP, Everett DF et al (1999) Spondyloarthropathy in the community: clinical syndromes and disease manifestations in Alaskan Eskimo populations. J Rheumatol 26:1537–1544PubMed

Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway. Ann Rheum Dis 44:359–367PubMedCrossRef

Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67. doi:10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-GPubMedCrossRef

Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A et al (1999) Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Sociètè de Rhumatologie de l’Ouest. J Rheumatol 26:2622–2627PubMed

Calin A, Brophy S, Blake D (1999) Impact of sex on inheritance of ankylosing spondylitis: a cohort study. Lancet 354:1687–1690. doi:10.1016/S0140-6736(99)03219-5 PubMedCrossRef

Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136:896–907PubMed

Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Clin Rheum 20:401–417. doi:10.1016/j.berh.2006.02.001 CrossRef

10.

Rudwaleit M, Metter A, Listing J, Sieper J, Braun J (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54:569–578. doi:10.1002/art.21619 PubMedCrossRef

11.

Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL et al (1997) Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 40:1823–1828. doi:10.1002/art.1780401015 PubMedCrossRef

12.

Laval SH, Timms A, Edwards S, Bradbury L, Brophy S, Milicic A et al (2001) Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 68:918–926. doi:10.1086/319509 PubMedCrossRef

13.

Said-Nahal R, Miceli-Richard C, Berthelot L, Duché A, Dernis-Labous E, Le Blévec G et al (2000) The familial form of spondyloarthropathy: a clinical study of 115 multiplex families. Groupe Français d’Etude Génétique des Spondyloarthropathies. Arthritis Rheum 43:1356–1365. doi:10.1002/1529-0131(200006)43:6<1356::AID-ANR20>3.0.CO;2-YPubMedCrossRef

14.

Martinez-Borra J, Gonzalez S, López-Vazquez A, Gelaz MA, Armas JB, Kanga U et al (2000) HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 61:131–139. doi:10.1016/S0198-8859(99)00145-7 PubMedCrossRef

15.

Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E et al (2000) Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66:1833–1844. doi:10.1086/302932 PubMedCrossRef

16.

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606. doi:10.1038/35079114 PubMedCrossRef

17.

Hugot JP, Chamaillard M, Zouali H, Lesage S, Cèzard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603. doi:10.1038/35079107 PubMedCrossRef

18.

Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al (2001) Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 357:1925–1928. doi:10.1016/S0140-6736(00)05063-7 PubMedCrossRef

19.

Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D et al (2005) CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 64:930–935. doi:10.1136/ard.2004.028837 PubMedCrossRef

20.

Zurück zum Zitat Wellcome Trust Case Control Consortium Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskivina V, Nikolov I, O’Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop TD, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Matthew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop MG, Connell J, Dominiczak A, Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hilder SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Frayling TM, Freathy RM, Lango H, Perry JR, Shields BM, Weedon MN, Hattersley AT, Hitman GA, Walker M, Elliott KS, Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Breast Cancer Susceptibility Collaboration (UK), Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widden C, Withers D, Cardin NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdo’ttir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Brown MA, Compston A, Farrall M, Hall AS, Hattersley AT, Hill AV, Parkes M, Pembrey M, Stratton MR, Mitchell SL, Newby PR, Brand OJ, Carr-Smith J, Pearce SH, McGinnis R, Keniry A, Deloukas P, Reveille JD, Zhou X, Sims AM, Dowling A, Taylor J, Doan T, Davis JC, Savage L, Ward MM, Learch TL, Weisman MH, Brown M (2007) Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39:1329–1337PubMedCrossRef Wellcome Trust Case Control Consortium Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskivina V, Nikolov I, O’Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop TD, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Matthew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop MG, Connell J, Dominiczak A, Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hilder SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Frayling TM, Freathy RM, Lango H, Perry JR, Shields BM, Weedon MN, Hattersley AT, Hitman GA, Walker M, Elliott KS, Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Breast Cancer Susceptibility Collaboration (UK), Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widden C, Withers D, Cardin NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdo’ttir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Brown MA, Compston A, Farrall M, Hall AS, Hattersley AT, Hill AV, Parkes M, Pembrey M, Stratton MR, Mitchell SL, Newby PR, Brand OJ, Carr-Smith J, Pearce SH, McGinnis R, Keniry A, Deloukas P, Reveille JD, Zhou X, Sims AM, Dowling A, Taylor J, Doan T, Davis JC, Savage L, Ward MM, Learch TL, Weisman MH, Brown M (2007) Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39:1329–1337PubMedCrossRef

21.

Mapstone R, Woodrow JD (1975) HL-A 27 and acute anterior uveitis. Br J Opthal 59:270–275. doi:10.1136/bjo.59.5.270 CrossRef

22.

Rosenbaum JT (1989) Characterization of uveitis associated with spondyloarthritis. J Rheumatol 16:792–796PubMed

23.

Rothova A, van Veenedall MS, Linssen A, Glasius E, Kijlstra A, de Jong PT (1987) Clinical features of acute anterior uveitis. Am J Ophthalmol 103:137–145PubMed

24.

Lyons JL, Rosenbaum JT (1997) Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 115:61–64PubMed

25.

Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT (2000) Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 59:67–70. doi:10.1136/ard.59.1.67 PubMedCrossRef

26.

Manguso F, Sanges M, Staiano T, Gargiulo S, Nastro P, Gargano D et al (2004) Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 99:327–334. doi:10.1111/j.1572-0241.2004.04039.x PubMedCrossRef

27.

Jacobs JC, Berdon WE, Johnston AD (1982) HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 100:521–528. doi:10.1016/S0022-3476(82)80746-4 PubMedCrossRef

28.

Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H et al (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62:829–834. doi:10.1136/ard.62.9.829 PubMedCrossRef

29.

Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N et al (2006) The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 26:663–668. doi:10.1007/s00296-005-0044-9 PubMedCrossRef

30.

Demetter P, Baeten D, De Keyser F, De Vos M, Van Damme N, Verbruggen G et al (2000) Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 59:211–216. doi:10.1136/ard.59.3.211 PubMedCrossRef

31.

Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387–398. doi:10.1016/S1074-7613(00)80038-2 PubMedCrossRef

32.

Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364. doi:10.1084/jem.180.6.2359 PubMedCrossRef

33.

Hyla JF, Franck WA, Davis JS (1976) Lack of association of HLA B27 with radiographic sacroiliitis in inflammatory bowel disease. J Rheumatol 3:196–200PubMed

34.

Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J et al (2003) Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 30:518–522PubMed

35.

Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF (1999) NF-κB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 163:1457–1466PubMed

36.

De Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M (2000) Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 27:2860–2865PubMed

37.

Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L et al (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed

38.

Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed

39.

Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 45:129–138. doi:10.1093/rheumatology/kei171 CrossRef

40.

Wang J, Elewaut D, Veys EM, Verbruggen G (2003) Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum 48:1281–1291. doi:10.1002/art.11061 PubMedCrossRef

41.

Wang J, Verdonk P, Elewaut D, Veys EM, Verbruggen G (2003) Homeostasis of the extracellular matrix of normal and osteoarthritis human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage 11:801–809. doi:10.1016/S1063-4584(03)00168-7 PubMedCrossRef

42.

Moos V, Fickert S, Müller B, Weber U, Sieper J (1999) Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 26:870–879PubMed

43.

Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 6:225–230PubMed

44.

Verbruggen G, Veys EM (1996) Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 39:308–320. doi:10.1002/art.1780390221 PubMedCrossRef

45.

Verbruggen G, Wittoek R, Groeneboer S, Cruyssen BV, Goemaere S, Elewaut D (2007) Osteochondral repair in synovial joints. Curr Opin Rheumatol 19:265–271. doi:10.1097/BOR.0b013e3280be58ff PubMedCrossRef

46.

Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876–1886. doi:10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-FPubMedCrossRef

47.

van Tubergen A, van der Heijde D, Anderson J, Landewé R, Dougados M, Braun J et al (2003) Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 62:215–221. doi:10.1136/ard.62.3.215 PubMedCrossRef

48.

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMed

49.

Spoorenberg A, van der Heijde S, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) A comparative study of the usefulness of the bath ankylosing spondylitis functional index and the Dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 26:961–965PubMed

50.

van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S (1997) Preliminary core sets of endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24:2225–2229PubMed

51.

Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61(suppl III):iii40–iii50PubMed

52.

Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J, ‘ASsessment in AS’ international working group European League Against Rheumatism (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452. doi:10.1136/ard.2005.041137 PubMedCrossRef

53.

Toussirot E, Wendling D (1998) Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 56:225–240. doi:10.2165/00003495-199856020-00006 PubMedCrossRef

54.

Wanders A, van der Heijde D, Landewè R, Béhier JM, Calin A, Olivieri I et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756–1765. doi:10.1002/art.21054 PubMedCrossRef

55.

Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296–298. doi:10.1136/ard.2004.023176 PubMedCrossRef

56.

Haibel H, Ruwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64:124–126. doi:10.1136/ard.2003.019174 PubMedCrossRef

57.

van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE (2005) Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 64:1761–1764. doi:10.1136/ard.2005.036491 PubMedCrossRef

58.

Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M et al (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66:419–421. doi:10.1136/ard.2006.054098 PubMedCrossRef

59.

Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E et al (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618–627. doi:10.1002/art.1780380507 PubMedCrossRef

60.

Clegg DO, Reda DJ, Weismann MH, Blackbrun WD, Cush JJ, Cannon GW et al (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2004–2012. doi:10.1002/art.1780391209 PubMedCrossRef

61.

Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ et al (1984) Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27:376–381. doi:10.1002/art.1780270403 PubMedCrossRef

62.

Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Treatment of Psoriatic Arthritis Study Group et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950. doi:10.1002/art.20253 PubMedCrossRef

63.

Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59:135–140. doi:10.1136/ard.59.2.135 PubMedCrossRef

64.

Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X et al (2001) Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60:316–321. doi:10.1136/ard.60.4.316 PubMedCrossRef

65.

Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505. doi:10.1002/art.1780380407 PubMedCrossRef

66.

Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46:755–765. doi:10.1002/art.511 CrossRef

67.

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of the Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591. doi:10.1002/art.20852 PubMedCrossRef

68.

Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Investigators (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157. doi:10.1136/ard.2004.032268 PubMedCrossRef

69.

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48:2224–2233. doi:10.1002/art.11104 PubMedCrossRef

70.

Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44:670–676. doi:10.1093/rheumatology/keh584 CrossRef

71.

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67:340–345. doi:10.1136/ard.2007.075879 PubMedCrossRef

72.

Van den Bosch F, Devinck M, Kruithof E, Verbruggen G, De Keyser F, Mielants H et al (2005) 5-year safety and efficacy follow-up in 107 spondyloarthropathy patients with continued long-term infliximab treatment. Ann Rheum Dis 64(suppl III):330. doi:10.1136/ard.2004.022111

73.

Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821–1822. doi:10.1016/S0140-6736(00)03239-6 PubMedCrossRef

74.

Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76. doi:10.1136/ard.62.1.74 PubMedCrossRef

75.

Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57:639–647. doi:10.1002/art.22669 PubMedCrossRef

76.

Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439–R444. doi:10.1186/ar1693 PubMedCrossRef

77.

Mease PJ, Kivitiz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264–2272. doi:10.1002/art.20335 PubMedCrossRef

78.

van der Heijde DM, Landewè RDM, Ory P, Vosse D, Zhou L, Tsuji W et al (2006) Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 65(suppl II):81. doi:10.1136/ard.2005.037671

79.

van der Heijde D, Landewè R, Deodar A, Baker D, Han J, Xu W et al (2007) Radiographic progression in patients with ankylosing spondylititis after 2 years of treatment not inhibited with infliximab. Ann Rheum Dis 66(suppl II):85

80.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376. doi:10.1002/art.21978 PubMedCrossRef

81.

Carmona L, Gòmez-Reino JJ, Rodrìguez-Valverde V, Montero D, Pascual-Gòmez E, Mola EM, BIOBADASER Group et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772. doi:10.1002/art.21043 PubMedCrossRef

82.

Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104. doi:10.1056/NEJMoa011110 PubMedCrossRef

83.

Furst DE, Cush J, Kaufmann S, Siegal J, Kurth R (2002) Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 61(suppl 2):ii2–ii3. doi:10.1136/ard.61.5.476 PubMed

84.

Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155. doi:10.1016/S1473-3099(03)00545-0 PubMedCrossRef

Titel: Clinical observations programme in SpA: disease parameters, treatment options and practical management issues
verfasst von: Dirk Elewaut
Filip Van den Bosch
Gust Verbruggen
Filip de Keyser
Bert Vander Cruyssen
Herman Mielants
Publikationsdatum: 01.01.2009
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 3/2009
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0714-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Health-related quality of life in patients with common rheumatic diseases referred to a university clinic

No significant association between genetic polymorphisms in the TNAP gene and ankylosing spondylitis in the Chinese Han population

Rapidly developed huge bursitis associated with scapular osteochondroma of the multiple exostosis: a case report

A case of limited systemic sclerosis with p-ANCA, complicated by multiple cerebral hemorrhages

The development of dysphagia and dysphonia due to anterior cervical osteophytes